论文部分内容阅读
目的 观察抗痨Ⅰ号辅助治疗结核性淋巴结炎的疗效。方法 将结核性淋巴结炎患者 60例随机分为治疗组 3 0例 ,服用抗痨Ⅰ号加正规抗结核化疗 (2HRZE/7HRE)。对照组 3 0例正规抗结核化疗用量、用法同治疗组。结果 治疗组总有效率 97 7% (2 9/3 0 ) ,临床治愈率 86 7% (2 6/3 0 ) ,复发率 3 3 % (1/3 0 )分别与对照组总有效率46 7% (14 /3 0 ) ,临床治愈率 3 0 % (9/3 0 ) ,复发率 2 6 7% (8/3 0 )比较差异均有显著性 (P <0 0 1)。治疗组在淋巴结消肿、溃面愈合、改善影像学方面均优于对照 (P <0 0 1)。结论 抗痨Ⅰ号协同化疗不仅具有杀菌散结、加速溃疡面及窦道愈合、提高治愈率的作用 ,而且能降低复发率。
Objective To observe the curative effect of Kangbian Ⅰ adjuvant therapy for tuberculous lymphadenitis. Methods Sixty patients with tuberculous lymphadenitis were randomly divided into treatment group (n = 30) and anti-tuberculosis chemotherapy plus 2HRZE / 7HRE. Control group of 30 cases of formal anti-TB chemotherapy dosage, the same treatment group. Results The total effective rate was 97.7% (2 9/3 0) in the treatment group, the clinical cure rate was 86.7% (26/3 0), and the recurrence rate was 33% (1/3 0) respectively. The total effective rate was 46 The clinical cure rate was 30% (9/3 0) and the recurrence rate was 26.7% (8/3 0). The difference was significant (P <0.01). The treatment group was better than the control in lymph node swelling, ulceration healing and imaging (P <0.01). Conclusion Anti-tuberculosis Ⅰ synergistic chemotherapy not only has bactericidal Sanjie, accelerate the ulcer surface and sinus healing, improve the cure rate, and can reduce the recurrence rate.